According to a recent study, pain and pruritus are the main contributors to atopic dermatitis (AD) burden and poor health-related quality of life (HRQoL).
Study shows PsO patients with pruritis, sleep disturbances experience lower QoL in all domains
According to a recent study, psoriasis (PsO) patients with pruritis and related sleep disturbances showed a lower quality of life in all domains.
Researchers create new tool to predict psoriatic arthritis in psoriasis patients
Researchers developed a tool, called the Psoriatic Arthritis Risk Estimation Tool (PRESTO), using clinical variables to predict psoriatic arthritis (PsA) risk in psoriasis patients with reasonable accuracy.
Study shows patch tests for allergic contact dermatitis still effective in AD patients on dupilumab
According to a recent study, the use of dupilumab in patients with atopic dermatitis (AD) did not significantly affect the results of patch tests for allergic contact dermatitis.
Roflumilast shows efficacy in 95% of plaque psoriasis patients
According to a recent press release, roflumilast showed significant improvement in disease severity in 95% of plaque psoriasis patients by week 8.
Study suggests Covid-19 may be associated with increased incidence of psoriasis
According to a recent study, patients who have contracted Covid-19 may have a higher risk of developing psoriasis and other immune-mediated inflammatory diseases (IMID).
Colloidal oatmeal as efficacious as barrier cream in Black children with AD
According to a recent study, colloidal oatmeal 1% is efficacious in treating mild-to-moderate atopic dermatitis (AD) in Black children.
EADV 2023 Day 4 Afternoon: JAK Inhibitors and Inflammatory Skin Disease
Dr. Ronald B. Vender reports live from the 2023 EADV Congress in Berlin and gives insights into JAK inhibitors and patient aspects of inflammatory skin diseases.
EADV 2023 Day 4 Morning: Congress Presentations of Interest
Dr. Ronald B. Vender reports live from the 2023 EADV Congress in Berlin and discusses the most popular topics of interest during the 32nd EADV Conference.
EADV 2023 Day 3 Evening: Abrocitinib for Prurigo Nodularis in Chronic Pruritus
Dr. Fiona Lovegrove reports live from the 2023 EADV Congress in Berlin and discusses the late breaking presentation on the efficacy and safety of abrocitinib for prurigo nodularis in chronic pruritus.
HealthMinute.TV 